Guidance, NICE advice and quality standards In development

Skip to filtersSkip to results

Skip to results

Expected publication date

Expected publication date

Area of interest

Area of interest

Type 1 selected

Type

Guidance programme

Showing 151 to 200 of 372

TitleTypeExpected publication date
12 SQ-HDM SLIT for treating allergic rhinitis and allergic asthma caused by house dust mites (review of TA834) [ID6280]Technology appraisal guidance
Direct skeletal fixation of limb or digit prostheses using intraosseous transcutaneous implantsInterventional procedures guidance
Fedratinib for treating disease-related splenomegaly or symptoms in myelofibrosis (Review of TA756) [ID5115]Technology appraisal guidance
Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection (Review of TA761) [ID5120]Technology appraisal guidance
Digitally enabled therapy for chronic tic disorders and Tourette SyndromeMedical technologies guidance
Hydromethylthionine mesylate for treating mild cognitive impairment or mild or moderate dementia caused by Alzheimer's disease ID6343Technology appraisal guidanceTBC
Linzagolix for treating pain caused by endometriosis [ID6357]Technology appraisal guidanceTBC
Givinostat for treating Duchenne muscular dystrophy in people 6 years and over [ID6323]Technology appraisal guidanceTBC
Elafibranor for treating primary biliary cholangitis [ID6331]Technology appraisal guidanceTBC
Avapritinib for treating advanced systemic mastocytosis ID3770Technology appraisal guidanceTBC
Epcoritamab for treating relapsed or refractory follicular lymphoma after 2 or more treatments [ID6338]Technology appraisal guidanceTBC
Venetoclax with bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma ID1565Technology appraisal guidanceTBC
Nusinersen and risdiplam for treating spinal muscular atrophy (review of TA588 and TA755) [ID6195]Technology appraisal guidance
Tafamidis for treating transthyretin amyloidosis with cardiomyopathy [ID6327]Technology appraisal guidance
Teclistamab for treating relapsed or refractory multiple myeloma after 3 treatments (Review of TA869) [ID6333]Technology appraisal guidance
Cerliponase alfa for treating neuronal ceroid lipofuscinosis type 2 (review of HST12) [ID6145]Technology appraisal guidance
Artificial intelligence (AI) technologies for assessing skin lesions referred on the urgent suspected cancer pathwayHealth technology evaluationTBC
Marstacimab for treating severe haemophilia A or severe haemophilia B in people 12 years and over [ID6342]Technology appraisal guidanceTBC
Pitolisant for treating narcolepsy in children and young people 6 to 17 years ID6353Technology appraisal guidanceTBC
Eplontersen for treating polyneuropathy caused by hereditary transthyretin amyloidosis [ID6337]Technology appraisal guidance
Vepdegestrant for treating hormone receptor-positive HER2-negative metastatic breast cancer after endocrine treatment [ID6360]Technology appraisal guidanceTBC
Datopotamab deruxtecan for previously treated hormone receptor-positive HER2-negative unresectable or metastatic breast cancer [ID6348]Technology appraisal guidanceTBC
Pembrolizumab–vibostolimab with etoposide and platinum-based chemotherapy for untreated extensive-stage small-cell lung cancer [ID6361]Technology appraisal guidanceTBC
Osimertinib with pemetrexed and platinum-based chemotherapy for untreated EGFR mutation-positive advanced non-small-cell lung cancer [ID6328]Technology appraisal guidanceTBC
Molnupiravir for treating COVID 19 [ID6340]Technology appraisal guidance
Maralixibat for treating progressive familial intrahepatic cholestasis [ID3818]Technology appraisal guidanceTBC
Odevixibat for treating cholestasis and pruritus in Alagille Syndrome [ID6181]Technology appraisal guidanceTBC
Pegzilarginase for treating arginase-1 deficiency [ID4029]Highly specialised technology
Idebenone for treating visual impairment in Leber's hereditary optic neuropathy in people 12 years and over [ID547]Technology appraisal guidanceTBC
Maralixibat for treating cholestatic pruritus in Alagille syndrome [ID3941]Technology appraisal guidance
Brentuximab vedotin with doxorubicin, dacarbazine and vinblastine for previously untreated late-stage classical Hodgkin lymphoma (including Review of TA594) [ID6334]Technology appraisal guidance
Nivolumab for adjuvant treatment of localised renal cell carcinoma [ID6362]Technology appraisal guidanceTBC
Pembrolizumab with chemotherapy for treating platinum-resistant recurrent ovarian cancer after 1 or 2 treatments [ID6363]Technology appraisal guidanceTBC
Iodine (131I)–apamistamab for treating relapsed or refractory acute myeloid leukaemia before an allogeneic haematopoietic stem cell transplant [ID6355]Technology appraisal guidanceTBC
Tarlatamab for previously treated advanced small-cell lung cancer [ID6364]Technology appraisal guidance
Transcatheter heart valves for transcatheter aortic valve implantation in people with aortic stenosis: Late stage assessmentHealth technology evaluation
Alectinib for adjuvant treatment of ALK-positive non-small-cell lung cancer [ID6368]Technology appraisal guidance
Leriglitazone for treating andrenoleukodystrophy [ID3903]Technology appraisal guidanceTBC
ALXN1840 for treating Wilson disease TS ID 9950Technology appraisal guidanceTBC
Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer (MA review of TA529) [ID6289]Technology appraisal guidance
Digital supported self-management technologies for adults with chronic obstructive pulmonary disease: early value assessmentHealth technology evaluation
Amyotrophic lateral sclerosis - SAR443820 [ID6386]Technology appraisal guidanceTBC
Selective internal radiation therapy with QuiremSpheres for treating unresectable advanced hepatocellular carcinoma (Partial review of TA688) [ID6376]Technology appraisal guidance
Tucatinib with trastuzumab emtansine for treating HER2-positive unresectable or advanced breast cancer after a taxane, trastuzumab or both together [ID6165]Technology appraisal guidanceTBC
Zanubrutinib for treating relapsed or refractory mantle cell lymphoma after 1 or more treatments [ID6392]Technology appraisal guidanceTBC
Selpercatinib for previously treated RET fusion-positive advanced non-small-cell lung cancer (MA review of TA760) [ID6293]Technology appraisal guidance
Artificial intelligence software to help detect fractures in the emergency department (provisional title)Health technology evaluation
Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia when there is no 17p deletion or TP53 mutation and FCR (fludarabine, cyclophosphamide, rituximab) or BR (bendamustine, rituximab) are suitable [ID6291]Technology appraisal guidanceTBC
Sotorasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer (MA review of TA781) [ID6287]Technology appraisal guidance
Cobolimab with dostarlimab and docetaxel for treating advanced non-small-cell lung cancer after anti-PD-L1 treatment and chemotherapy [ID6398]Technology appraisal guidanceTBC

Results per page

  1. 10
  2. 25
  3. 50
  4. All